In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing Klebsiella pneumoniae Clinical Isolates [PDF]
Antibiotics, 2023 The novel β-lactam/β-lactamase inhibitor combinations (βL-βLICs) are one of the last-line resources available against multidrug-resistant (MDR) Gram-negative bacteria.
Marta Palombo +5 more
doaj +2 more sources
Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
Antibiotics, 2021 Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and ...
George L. Daikos +6 more
doaj +2 more sources
Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature [PDF]
Antibiotics, 2023 Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and ...
Alessandro Mancuso +5 more
doaj +2 more sources
Emergence of Ceftazidime-Avibactam-Induced KPC Variants (KPC-25/127) in Intracranial Infection and Implications for Clinical Management. [PDF]
MicrobiologyopenNovel KPC‐25 and first‐reported KPC‐127 sequentially evolved in one patient under CAZ‐AVI pressure, distinct mutations remodel enzyme activity to drive differential multidrug resistance. ABSTRACT The emergence of novel Klebsiella pneumoniae carbapenemase (KPC) variants contributing to clinical treatment failure poses a substantial threat to public ...
Lei K +8 more
europepmc +2 more sources
Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia: A Case Report. [PDF]
Clin Case RepABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zhou Z +6 more
europepmc +2 more sources
, 2021 Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Xiangning Huang (5216384) +6 more
core +1 more source
Microorganisms, 2020 Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang +10 more
doaj +1 more source
Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
Emerging Infectious Diseases, 2023 We identified a novel ceftazidime/avibactam resistance mechanism in sequence type 11 Klebsiella pneumoniae carbapenemase 2–producing K. pneumoniae.
Qiaozhen Cui +6 more
doaj +1 more source
Antimicrobial Resistance and Infection Control, 2020 Background This study reports the global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam using data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program between 2012 and 2016.
Hui Zhang +12 more
doaj +1 more source
, 2021 Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Xiangning Huang (5216384) +6 more
core +1 more source